Patents Assigned to Aventis Pharmaceuticals Inc.
  • Patent number: 8828974
    Abstract: The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: September 9, 2014
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Yong Mi Choi-Sledeski, Julian Levell, Gregory Bernard Poli, Mark Czekaj, Alan John Collis, Roy Vaz
  • Patent number: 8809270
    Abstract: This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 19, 2014
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Ralf Rosskamp, Hertzel Gerstein
  • Publication number: 20140073670
    Abstract: The present invention relates to a pharmaceutical formulation of fexofenadine hydrochloride in a solvent system suitable as a liquid fill composition. In another aspect, the invention also relates to a process for the preparation of the pharmaceutical formulation and the use of the composition for the treatment of allergic reactions in a patient.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 13, 2014
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Sudhakara Rao BADABHAGNI, Nilesh JAISWAL, Praveen KHULLAR, Kum PRASAD
  • Patent number: 8642739
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: February 4, 2014
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrice Denefle, Thomas F. Haws, June M. Kaplow, Marie Rosier
  • Patent number: 8623831
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: January 7, 2014
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrice Denefle, Thomas F. Haws, June M. Kaplow, Marie Rosier
  • Publication number: 20130012433
    Abstract: This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Ralf ROSSKAMP, Hertzel GERSTEIN
  • Publication number: 20130005728
    Abstract: The present invention is directed to a substituted pyrimidine compound of formula (I) or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.
    Type: Application
    Filed: September 11, 2012
    Publication date: January 3, 2013
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Keith J. HARRIS, Joacy C. AGUIAR, Patrick Wai-Kwok SHUM, Zhicheng ZHAO, Gregory B. POLI, Gregory STOKLOSA, Yong-Mi CHOI-SLEDESKI, Stephan REILING, David STEFANY, Charles GARDNER
  • Publication number: 20130005741
    Abstract: The present invention is directed to a 2,6-substituted-4-monosubstitutedamino-pyrimidine compound of formula (I): or an enantiomer thereof, or an ester prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.
    Type: Application
    Filed: September 11, 2012
    Publication date: January 3, 2013
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Keith John HARRIS, Joacy C. AGUIAR, Patrick Wai-Kwok SHUM, Zhicheng ZHAO, Gregory B. POLI, Gregory T. STOKLOSA, Yong-Mi CHOI-SLEDESKI, Stephan REILING
  • Patent number: 8343494
    Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: January 1, 2013
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
  • Patent number: 8288425
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: October 16, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry
  • Publication number: 20120208784
    Abstract: The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.
    Type: Application
    Filed: April 24, 2012
    Publication date: August 16, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Yong Mi CHOI-SLEDESKI, Julian LEVELL, Gregory Bernard POLI, Mark CZEKAJ, Alan John COLLIS, Roy VAZ
  • Publication number: 20120202795
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Philip M. WEINTRAUB, Paul R. EASTWOOD, Shujaath MEHDI, David W. STEFANY, Kwon Yon MUSICK, Neil MOORCROFT, Sungtaek LIM, John Z. JIANG, Hartmut RUTTEN, Stefan PEUKERT, Uwe SCHWAHN
  • Patent number: 8202863
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2, R3 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: June 19, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Suzanne C. Aldous, John Ziqi Jiang, Jinqi Lu, Liang Ma, Lan Mu, Harry Randall Munson, Jeffrey Stephen Sabol, Sukanthini Thurairatnam, Christopher Loren Vandeusen
  • Patent number: 8193183
    Abstract: The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischem
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: June 5, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Sungtaek Lim, Keith John Harris, David Stefany, Charles J. Gardner, Bin Cao, Ray Boffey, Timothy A. Gillespy, Joacy C. Aguiar, Hazel J. Dyke, Elsa A. Dechaux
  • Patent number: 8183231
    Abstract: The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: May 22, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Yong Mi Choi-Sledeski, Julian Levell, Gregory Bernard Poli, Mark Czekaj, Alan John Collis, Roy Vaz
  • Publication number: 20120114660
    Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.
    Type: Application
    Filed: July 15, 2009
    Publication date: May 10, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
  • Patent number: 8173682
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: May 8, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Philip M. Weintraub, Paul R. Eastwood, Shujaath Mehdi, David W. Stefany, Kwon Yon Musick, Neil Moorcroft, Sungtaek Lim, John Z. Jiang, Hartmut Rutten, Stefan Peukert, Uwe Schwahn
  • Publication number: 20120034188
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Application
    Filed: August 1, 2011
    Publication date: February 9, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Kun Guo, Marco F. Pagnoni, Kenneth L. Clark, Yuri D. Ivashchenko
  • Publication number: 20110281793
    Abstract: This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 17, 2011
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Ralf Rosskamp, Hertzel Gerstein
  • Patent number: 8053458
    Abstract: The present invention is directed to dipyrazole compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I. The compounds of this invention modulate AMPA and NMDA receptor function, and therefore are useful as pharmaceutical agents, especially for the treatment of neuropsychiatric disorders.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: November 8, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Raymond W. Kosley, Douglas MacDonald, Rosy Sher